



PRESCRIPTION

PATIENT ACCESS

PREPARATION

APPLICATION

DISCHARGE MANAGEMENT

Cyto-Set®

Advanced preparation and administration of hazardous drugs

NOW FEATURING AIRSTOP TECHNOLOGY

Challenges in Chemotherapy

Intravenous chemotherapy is one of the most challenging processes within the infusion therapy field. Starting with the preparation of the drug, by way of transportation, administration to the patient and disposal after the treatment, healthcare workers, physicians, pharmacists and also patients are at risk of adverse consequences. International guidelines stipulate the special handling of cytostatic drugs to reduce risks during the process. In line with the regulatory requirements Cyto-Set supports the healthcare provider to prevent the following risks:



Chemical Contamination

• Unintended exposure of a healthcare professional to hazardous drugs.

Possible consequences

 Toxic contamination can lead both to acute symptoms (nausea, diarrhea, throat irritation, skin rashes, hair loss, even mutagenicity) or chronic symptoms (carcinogenicity, secondary malignant neoplasia due to the exposure to high doses of cytotoxic medication, reproductive effects).^{1,2}



Drug Incompatibilit

• Undesirable reaction that occurs between the drug and a) the IV solution b) the container or c) another drug.

Possible consequences^{3, 4, 5}

- Damage from toxic drugs (e.g. dermatitis, antibiotics hypersensitivity)
- Particulate emboli from crystallization and separation (thrombophlebitis up to multi-organ failure)
- Tissue irritation due to major pH changes
- Therapeutic failure due to the reduction or elimination of the active drug



Microbiological Contamination

- Infection which a patient incurs in a healthcare facility and which was not present at the time of admission. (incl. infections acquired in the hospital but appearing after discharge, and also occupational infections among the staff of the facility.)
- Infections are caused by microbiological pathogens like bacteria, viruses, prions or fungi, as well as by toxins and by-products that these pathogens release.

Possible consequences

- Local infection consequences: surgical wound infections, skin irritations and catheter entry site infections
- Systemical inflammation consequences (pathogens reaching the systemic circulation): septicemia, sepsis and septic shock ^{6, 7}




Particulate Contamination

• Unintended presence of extraneous, mobile and undissolved particles in a parenteral solution.

Possible consequences

 Unfavorable effects (phlebitis, damage lungs⁸, kidneys, nodular fibrosis of the liver and spleen, granulomatous lung disease, myocarditis, occult pulmonary granulomas to local tissue infarction and pulmonary infarction)⁹



Medication Error

• An error in prescribing, dispensing or administering of a drug, irrespective of whether such errors lead to adverse consequences or not.

Possible consequences¹⁰

• Errors in IV drug preparation can have a broad range of consequences ranging from harmless to serious.



Sharp Injuries

Skin penetrating stab wounds caused by sharp instruments and accidents in a medical setting.
 These instruments include needles, lancets, scalpels and broken glass.

Possible consequences

• The main concern regarding a needle stick injury (NSI) is not the physical trauma itself, but rather the percutaneous exposure to a patient's blood and body fluids (BBF) which may carry infectious diseases.11 The likelihood of developing a disease after a NSI depends on various independent factors: pathogen concentration in the blood and body fluids, depth of the wound, blood volume, amount of pathogens transmitted and the infection phase of the pathogen carrier.



DEHP-Exposure

• Polyvinyl chloride (PVC) plastic is used to manufacture a huge number of articles for daily life, e.g. toys, building material such as flooring, cables, as well as medical products. Unplasticized PVC is hard and brittle at room temperature. As a result, plasticizers are necessary to impart flexibility to the polymer.

Possible consequences

Health concerns about phthalate plasticizers are currently the subject of considerable media, legislative
and scientific debate. The exposure of human beings and especially developing children to DEHP can have
significant health consequences.¹²



Air Embolism

• Vascular air embolism is the entrainment of air (or exogenously delivered gas) from the operative field or other communications with the environment into the venous or arterial vasculature, producing systemic effects.

Possible consequences

- The symptons and clonical signs of air embolism are related to the degree of air entry into the circulation system. They usually develop immediately after embolization. 13
- Air embolism can have a broad range of consequences ranging from harmless to serious.

Risk Reduction with Cyto-Set®



The new and improved Cyto-Set® design is in line with our Safe Infusion Therapy concept to protect clinicians and patients in the field of drug preparation.

The comprehensive portfolio of Cyto-Set® offers a high safety standard of each component. During administration on the ward the new Cyto-Set® portfolio not only improves handling but also increases safety.

The flexibility of Cyto-Set® offers convenient solutions for the application of cytostatic drugs across different clinical requirements. When used together Cyto-Set® Mix, Cyto-Set® Infusion and Cyto-Set® Infusomat® Space provide a closed system from preparation in the pharmacy to administration to the patient, all the way to the disposal of the Cyto-Set® system after treatment.



Di-I-	Cafata Faatuus	Cofety Day Ch		
Risk	Safety Feature	Safety Benefits		
Chemical Contamination	Needle-free valve	 Helps to reduce the risk of chemical contamination as the valves are designed for preventing spillage/drug exposure.¹⁴ 		
Microbiological Contamination	Finger stopper and finger grip	 Reduction of microbial contamination due to the finger stopper and finger grip.¹⁵ 		
	PrimeStop	 Improved safety against microbial contamination due to the hydrophobic, bacteria retentive PrimeStop cap on the patient connector which provides a closed system until connection to the patient.^{16, 17} 		
	• Needle-free valve	 Provides easy access, while helping to reduce the chance of accidental touch contamination.¹⁸ 		
	 Air vent filter in the spike 	• The bacteria tight air vent filter in the spike reduces the contamination risk of the infusion solution. ¹⁹		
Drug Incompatibility	Grip plate with integrated back check valves	 Integrated back check valves improve safety by reducing risk of unintended mixture of drugs.²⁰ 		
Particulate Contamination	• 15 μm filter in the drip chamber	• A particle filter in the drip chamber with pore size of 15 μ m prevents the infusion of particles from the infusion container. ²¹		
	• 0.2 µm Sterifix® filter	- The 0.2 μm Sterifix® filter (where fitted) retains bacteria, fungi, particles and air.		
Sharps Injury	 Needle-free valve 	 Provides needle-free access, eliminating the risk of needlestick injuries.^{22, 23} 		
Medication Error	Structure of the regime	• Due to the 90° angle of the valves in the grip plate, the whole Cyto-Set® regime is structured well, which reduces the risk of mistaking the drugs within the therapy.		
Air Embolism	AirStop	AirStop function in drip chamber reduces the risk of air embolism. ²⁴		
DEHP Exposure	PVC / DEHP free tubing	All lines are PVC-free, there is no risk of DEHP exposure.		

A Proven Closed System*

INNOVATION IN DESIGN AND TECHNOLOGY

Improved design of Cyto-Set® offers a higher level of patient and user safety due to it's new features. In addition to this, these features support the usability of the new portfolio due to the intuitive handling of the IV-Set.


Cyto-Set® is a closed system*, and the new portfolio has been tested according to NIOSH guidelines.* No disconnection during the treatment or afterwards are necessary to dispose of the system.

YOUR BENEFITS

- Cytostatic resistant material "Tritan™" is used for the needle-free valve to avoid the risk of chemical contamination caused by stress-cracking.
- Systematic arrangement of the needle-free valves help to reduce the risk of medication errors.
- Integrated back check valves to avoid drug incompatibilities and medication errors caused by reflux.
- Ergonomic design of grip plate and Y-site needle-free valve supports safe handling and helps to reduce risk of microbial contamination.
- Improved fluid flow leads to a reduced dead space volume of Y-site needle-free valve which decreases the risk of drug in compatibilities and air embolism.
- AirStop function in drip chamber prevents air entrainment into the infusion tubing and helps to reduce the risk of air embolism.



- * Cyto-Set® is tested according to NIOSH guidelines as a closed system. Confirmation available
- ** Bacteria tightness of PrimeStop Cap. Confirmation available.
- *** Filter prevents the escape of any contamination into the adjacent environment. Confirmation available



Drug Preparation in the Pharmacy



Priming of Cyto–Set $^{\scriptsize{\$}}$ Mix in the pharmacy

Protect yourself and your environment during the preparation of cytostatic drugs in the pharmacy by priming Cyto-Set® Mix first. Since cytostatic drugs can pose serious health hazards, Cyto-Set® Mix supports pharmacists by reducing the risk of contamination and helping to increase the process efficiency of drug admixture.

Handling Step
Close venting cap.

Safety Feature

Air vent filter in spike with integrated B.C.V. helps to avoid contamination during venting.

Handling Step

Spike the container.

Safety Feature

Container stability of Ecoflac® plus allows easy and convenient spiking while helping to reduce risks of sharps injuries.

Handling Step Prime the filter.


Safety Feature

0.2 μm Sterifix® filters particles larger than 0.2 μm which reduces the risk of particulate contamination.

Handling Step
Prime the line completely.

Safety Feature

Hydrophobic, bacteria retentive cap maintaining a closed system until connection to the main line without spillages of fluid.



Drug preparation in the pharmacy with Cyto-Set® Mix

During the admixture process, as well as Cyto-Set® Mix, other products from B. Braun's comprehensive portfolio can be utilised; such as the closed male connector PureSite, the semi-rigid container Ecoflac®plus and the luer-lock Omnifix® syringe.

Handling Step

Close white clamp close to the needle-free valve.

Safety Feature

Helps to avoid chemical contamination as the line will only contain inert carrier solution..

Handling Step

Connect prepared syringe with diluted drug to the needle-free valve by using the finger plate.

Safety Feature

Helps to reduce risk of microbiological contamination since no direct contact to the needle-free valve is needed. The needle-free valve prevents needle-stick injuries.

Handling Step


Inject drug into container and mix the solution well by aspirating once or twice.

Safety Feature

Drug is administered in accordance with the medical prescription..

PRESCRIPTION PATIENT ACCESS PREPARATION APPLICATION DISCHARGE MANAGEMENT

Application on the Ward



Priming of Cyto–Set $^{\tiny{\$}}$ main line on the ward

Cyto-Set® main line is designed for safer drug administration on the ward by supporting the concept of a safer handling process before, during and after the treatment. Cyto-Set® supports the process with features dedicated to the environment of an oncology ward.

Handling Step
Close venting cap.

Safety Feature

Air vent filter in spike with integrated B.C.V. to avoid contamination during venting.

Handling Step

Spike the container.

Safety Feature

Tight connection. Once inserted the spike stays firmly connected to reduce the chance of being disconnected accidentaly.

Handling Step

While allowing system to fill, hold the drip chamber upside down.

Safety Feature

Fluid filter in the drip chamber to avoid particular contamination.

Handling Step
Prime the line completely.

Safety Feature

Hydrophobic, bacteria retentive cap maintaining a closed system until connection to the main line without spillages of fluid.



Drug application on the ward with Cyto-Set® & Cyto-Set® Mix

The numbers of cytostatic drugs available on the market are increasing and their cost remains high. Residual volume left in the IV-Set, as well as drug incompatibilities, increases the risk of an ineffective treatment or of an inefficient process. The concept of Cyto-Set® supports the process by helping to increase efficiency, effectiveness and safety!

Handling Step

Close white clamp of main line.

Safety Feature

Closed clamp prevents a contamination of flushing solution to reduce the risk of drug incompatibilites.

Handling Step


Connect Cyto-Set® Mix to main line, open white clamp and start treatment.

Safety Feature

A tactile "click" will let the user know that the sets are connected.

PRESCRIPTION PATIENT ACCESS PREPARATION APPLICATION DISCHARGE MANAGEMENT

Application on the Ward and Disposal



Drug application on the ward with Cyto-Set® & Cyto-Set® Mix

In order to support effective treatment, Cyto-Set® enables the user to flush the IV-Set completely, delivering the whole dose in accordance with the medical prescription.

Handling Step

After each drug flush the line completely with flushing solution.

Safety Feature

The full amount of drug is given to the patient which helps to reduce the risk of medication errors.

Thanks to AirStop function the fluid level remains in the drip chamber after drug application. The line does not run dry which helps to prevent air embolism.

→ Handling Step

Open clamp of next Cyto-Set® Mix to start the next treatment.

Safety Feature

Flushing plus integrated back check valves helps to reduce the risk of drug incompatibilities.



Disposal as a complete system

Even after the treatment is finished, protection of staff, patients and the environment is vital. Cyto-Set® is disposed of easily and conveniently without any disconnection of the component parts and remains a closed system throughout.

■ Handling Step

Dispose as a closed system.

Safety Feature

Helps to avoid the risk of chemical contamination because no disconnection is necessary.

PRESCRIPTION PATIENT ACCESS PREPARATION APPLICATION DISCHARGE MANAGEMENT

Product Portfolio

Cyto-Set®	Product	Туре	Light protection	AirStop	Units per box	Code no. (REF)	
	Preparation						
	Cyto-Set® Mix	with 1 needle-free valve	-	-	20	A2900N	
		with 1 needle-free valve, with 0.2 µm filter	-	_		A2903N	
		with 1 needle-free valve		_		A2906N	
	Cyto-Set® Line	without needle-free valve		_		A2581NF	
		without needle-free valve, with 0.2 μm filter				A2582NF	
	Application (Pump) Infusomat® Space						
	Cyto-Set® Infusomat® Space	with 3 needle-free valves		-	20	8250917SP	
		with 3 needle-free valves	-	•		835917SP	
6 0		with 5 needle-free valves		-		8250817SP	
		with 5 needle-free valves		•		835817SP	
		with 3 needle-free valves	•	_		8250920SP	
		with 3 needle-free valves	•	•		835920SP	
		with 5 needle-free valves	•	-		8250820SP	
		with 5 needle-free valves		•		835820SP	
		with 5 needle-free valves, with 0.2 μm filter				8250414SP	
		with 5 needle-free valves, with 0.2 μm filter		•		835414SP	
	Cyto-Set® Pump Adapter	4 needle-free valves	_	-		A1673S0	

Literature

Literature

- McDiarmid MA, Egan T. Acute occupational exposure to antineoplastic agents. J Occup Med 1988; 30(12): 984–987
- Valanis GB, Vollmer WM, Labuhn KT, Glass AG. Association of antineoplastic drug handling with acute adverse effects in pharmacy personnel. Am J Hosp Pharm 1993b; 50; 455-462
- Fahimi F, Sefidani Forough A, Taghikhani S, Saliminejad L (2015) The rate of Physicochemical Incompatibilities, Administration Errors. Factors correlating with Nurses' errors. Iran J Pharm Res; 14(suppl); 87–93
- Vijayakumar A, Sharon EV, Teena J, Nobil S, Nazeer I. (2014) A clinical study on drug-related problems associated with intravenous drug administration. J Basic Clin Pharm; 5(2): 49–53
- Höpner JH, Schulte A, Thiessen J, Knuf M, Huth RG. (2007) Preparation of a compatibility chart for intravenous drug therapy in neonatal and pediatric intensive care units. Klin Padiatr; 219(1): 37-43
- Uslusoy E., Mete S.: Predisposing factors to phlebitis in patients with peripheral intravenous catheters: a descriptive study. J Am Acad Nurse Pract. 2008; 20(4): 172-80
- Bouchoucha et al. Deep venous thrombosis associated with acute hematogenous osteomyelitis in children. Orthop Traumatol Surg Res. 2010 Dec; 96(8): 890-3., Boucher 2010
- Dewan et al. 1995b; publications ex Dewan et al. 2002; Ewan PA, Stefanek W, Byard RW. Long-term response to intravenously injected Teflon and Silicone in a rat model. Pediatric Surgery Interantional 1995b; 10(2,3): 129–133
- Roth 2007, Lehr et al. 2002; Roth JV. How to enter a medication vial without coring. Anesth Analg 2007; 104(6): 1615
- Cousins DH, Sabatier B, Begue D, Schmitt C, Hoppe-Tichy T (2005) Medication errors in intravenous drug preparation and administration: a multicentre audit in the UK, Germany and France. OSHC 14: 190–195
- Canadian Center for Occupational Health and Safety (CCOHS); Needlestick injuries. 2000. (www.ccohs.ca/oshanswers/diseases/needlestick_injuries.html)
- National toxicology programm, the US department of health and human services
 (11/2006) HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/?term=NTP-CERHR+Mono graph+on+the+Potential+Human+Reproductive+and+Developmental+Effects+of+Di
 (2-Ethylhexyl)"Center for the evaluation of risks to human reproduction: NTP-CERHR Mono graph on the Potential Human Reproductive and Developmental Effects of Di(2-Ethylhexyl)
 Phthalate (DEHP). NIH Publication No. 06 4476.

- 13. Mirski et al. 2007 Wittenberg 2006, Josephson 2006, Perdue 2001
- Abstract Closed system test by means of Sodium Fluorescein signed by Dr. rer. nat. J. Brünke Quality Labs BT GmbH Nuremberg, Report 1816.3, 01.09.2015
- Abstract Evaluation of the microbial barrier performance of Cyto-Set® and Cyto-Set® Mix (NEW) signed by Prof. Dr. med. M.Exner and Dr. rer. nat. J. Gebel, Report DMT 2014–195, 23.02.2015
- Test Report Closed system test by means of Sodium Fluorescein signed by Dr. rer. nat. J. Brünke Quality Labs BT GmbH Nuremberg, Report 1678.3, 28.05.2013
- 17. Confirmation PrimeStop Cap Bacteria tightness of PrimeStop Cap. Confirmation available.
- Abstract Evaluation of the microbial barrier performance of Cyto-Set® and Cyto-Set® Mix (NEW) signed by Prof. Dr. med. M.Exner and Dr. rer. nat. J. Gebel, Report DMT 2014–195, 23.02.2015
- Confirmation Air vent filter Filter prevents the escape of any contamination into the adjacent environment signed by Andreas Katerkamp and Dr. Stefan Seidel, 01.11.2016
- Non-return valves do not prevent backflow and bacterial contamination of intravenous infusions written by B. Ellger, D. Kiski, E. Diem, I. van den Heuvel, H. Freise, H. Van Aken, F. Hinder, A. W. Friedrich, 11.03.2011, Journal of Hospital Infection
- 21. Confirmation ISO Standard ISO 8536-4 signed by Gudrun Henke and Caroline Führ, 01.02.2017
- American Nurses Association Independent Study Module: Needlestick Safety and Prevention written by Mary Foley, MS, RN and Annemarie T. Leyden, EdD, RN
- Review Article Review on Needle Free Drug Delivery Systems, International Journal of Pharma Research & Review, written by Bhagyashri Chavan, Abha Doshi, Yashwant Malode, Balu Misal, Sept 2013; 2(9):30-36
- Pheriphervenöse Schwerkraftinfusionen Intrafix® SafeSet mit Vorteilen gegenüber herkömmlichen Infusionssystemen written by lic. rer. pol. Andreas Frei, Die Schwester Der Pfleger 43. Jahrg. 5/04





For further information about Risk Prevention in Infusion Therapy, please refer to the Risk Prevention brochures or scan the QR-code and visit:

WWW.SAFEINFUSIONTHERAPY.COM